SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is facing downward pressure, with community members debating whether it's losing ground to gold as a safe haven asset. Speculation is swirling around a potential announcement and its possible impact, while others point to technical charts suggesting further declines. Community members are also discussing the potential impact of macro events on Bitcoin's price.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach new highs, driven by trade tensions and expectations of future rate cuts. The community is actively discussing whether this rally is sustainable or if a significant correction is on the horizon, with some seeing bubble-like conditions. Some traders point to potential factors that could either continue to fuel the run or trigger a pullback.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the potential impact of China's tightening battery export rules, which could favor the company's U.S.-based solid-state technology; the community is actively debating the stock's recent price action, with some seeing it as a buying opportunity while others express concerns about a possible pullback, also earnings are upcoming with investors hoping to see revenue.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders assess potential downside risk amid geopolitical tensions and anticipation of an upcoming announcement. Community members are weighing the possibility of a sharp reversal against concerns of deeper losses, with focus on key support levels. Discussions also involve broader market factors like bank performance and potential impacts from a former president's comments.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending due to its volatile Nasdaq debut, marked by multiple trading halts and a wide price range. The community is actively discussing entry points, potential shorting activity, and the company's long-term prospects in the solar EV market. Despite the initial turbulence, some investors remain optimistic about Aptera's technology and future potential.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders hedge against market uncertainty, with community members discussing potential upside driven by geopolitical tensions and economic data. Some are debating whether the recent moves signal a larger correction, while others are looking to profit from short-term volatility. The fund's movements are being closely watched amid broader concerns about market valuations and the potential impact of a government shutdown.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community debates the stock's valuation and potential catalysts, including Trump's involvement and the company's Bitcoin holdings. Discussions also involve the broader implications of tariffs and government spending. Concerns about dilution and the company's financial performance are prominent talking points.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending as traders discuss its recent surge following positive Phase 3 trial results for its essential tremor treatment, with analysts issuing bullish price targets. Community chatter revolves around short squeezes, potential profit-taking, and whether the company will pursue a dilutive offering. The stock is also being mentioned in the context of other bio stocks experiencing similar momentum.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to legal challenges in the UK concerning talc-related cancer claims, sparking a sell-off despite the company's denial of the allegations. Community discussions revolve around the potential liability for Kenvue versus J&J, the extent of the overreaction, and whether this presents a buying opportunity given the company's dividend and well-known brands. Some traders are looking at short-term call options, while others are considering longer-term positions based on value and potential bounce-back.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is trending amid developments in the legal landscape, including a lawsuit in the UK concerning talc-related cancer claims linked to Kenvue, its former consumer health unit. Simultaneously, investors are monitoring J&J's strategic shift, particularly its plan to spin off its Orthopaedics unit to sharpen its MedTech focus, while the community debates its potential impact and strategic rationale.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders PR...

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to...

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data

Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.

Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?

NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.

U.S. equities declined in Thursday afternoon trade as Wall Street took a breather following a record-setting rally. The S&amp;P 500 and the Nasdaq Composite indexes both climbed to record highs on Thursday, before paring the gains and declining to trade in the red at the time of writing.Meanwhile, silver prices&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/silver-spot-price-50-first-time-4-decades/ch67qedR3K8">continued to climb</a> on Thursday. Spot silver prices climbed to a new high of $51.38 per troy ounce, rising more than 5% before paring most of the gains.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.41% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, fell 0.45%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.52%.Here are the top stocks making the biggest moves in Thursday’s afternoon trade:<a href="https://stocktwits.com/symbol/DAL">Delta Air Lines Inc. (DAL)</a>Delta shares soared over 5% in Thursday’s afternoon trade after the airline’s third-quarter (Q3) results beat Wall Street expectations. Delta reported earnings per share (EPS) of $1.71 on revenue of $16.67 billion, beating analyst estimates of an EPS of $1.53 on revenue of $15.08 billion, according to Stocktwits data.<a href="https://stocktwits.com/symbol/DAL">DAL stock</a> is down 1% year-to-date.<a href="https://stocktwits.com/symbol/TLRY">Tilray Brands Inc. (TLRY)</a>Tilray Brands shares were up more than 23% in Thursday’s afternoon session after the company’s first-quarter (Q1)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-brands-stock-skyrockets-on-swing-to-profit-significant-debt-reduction/ch67ouWR3Kj">results</a> came in better than expectations. Tilray reported nil earnings per share (EPS) on revenue of $209.5 million, beating analyst estimates of a loss of $0.03 per share on revenue of $204.55 million, according to Stocktwits data.<a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> is up 59% year-to-date.<a href="https://stocktwits.com/symbol/PATH">UiPath Inc. (PATH)</a>UiPath shares climbed 15% in Thursday’s afternoon trade, building on the gains over the past few trading sessions following the announcement of collaboration with OpenAI on enterprise agentic automation. The stock surged over 5% on Wednesday and hit new 2025&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ui-path-rises-extended-hours-after-hitting-new-2025-highs/ch67O1jR30f">highs</a> on AI momentum.<a href="https://stocktwits.com/symbol/PATH">PATH stock</a> is up 41% year-to-date.<a href="https://stocktwits.com/symbol/AKRO">Akero Therapeutics Inc. (AKRO)</a>Akero Therapeutics shares were up more than 16% on Thursday after the company announced that it had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/akero-shares-rally-pre-market-after-announcing-acquisition-by-novo-nordisk/ch67VXUR3K7">entered</a> into a definitive agreement to be acquired by Novo Nordisk AS (NVO) for up to $5.2 billion in cash.<a href="https://stocktwits.com/symbol/AKRO">AKRO stock</a> is up 95% year-to-date.<a href="https://stocktwits.com/symbol/APGE">Apogee Therapeutics Inc. (APGE)</a>Apogee Therapeutics shares continued to gain on Thursday, rising more than 7% after surging 19% on Wednesday. The clinical-stage biotechnology company announced the pricing of a $300 million public offering at $41 per share.<a href="https://stocktwits.com/symbol/APGE">APGE stock</a> is up 12% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/silver-spot-price-50-first-time-4-decades/ch67qedR3K8">Silver Prices Hit $50 For First Time In Over 4 Decades</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today

Delta shares soared over 5% in Thursday’s afternoon trade after the airline’s third-quarter results beat Wall Street expectations.

Equity

Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Akero...

AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akero Therapeutics, Inc. (NASDAQ: AKRO) to Novo Nordisk A/S is fair to Akero shareholders. Under the terms of the...

U.S. stocks appear set for a cautious opening on Thursday as investors await a series of speeches from Federal Reserve officials, including Chair Jerome Powell, Vice Chair for Supervision Michelle Bowman, and a discussion between Fed Governor Michael Barr and Minneapolis Fed President Neel Kashkari.On Wednesday, the minutes of the Federal Open Market Committee’s (FOMC) September meeting were released,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-minutes-half-officials-expect-two-more-rate-cuts-by-end-of-2025/ch6EAFlR30c">highlighting concerns</a> among Fed officials about labor market weakness and the need for further rate cuts.While Dow Jones futures edged up by 0.01% at the time of writing, the S&amp;P 500 futures were down by 0.02%, while the tech-heavy Nasdaq 100’s futures fell 0.05%. Futures of the Russell 2000 index were down by 0.2%.Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was down 0.04% at the time of writing. Invesco QQQ Trust (QQQ) fell 0.08% on Thursday morning, and the SPDR<a href="https://stocktwits.com/symbol/DIA"> Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.03%. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘bearish’ territory.Asian markets ended Thursday’s trading session on a largely positive note, with the Nikkei 225 leading with gains of 1.6%, followed by the Shanghai Composite at 1.3%, and the TWSE Capitalization Weighted Stock index at 0.87%.The Hang Seng index declined 0.35%, while the KOSPI was closed for trading on account of Chuseok Festivity.Stocks To Watch<ul><li>Tesla Inc. (TSLA): The National Highway Traffic Safety Administration (NHTSA) opened a probe into nearly 2.9 million Tesla vehicles equipped with the company’s Full Self-Driving (FSD) system over more than 50 traffic safety violations and a few crashes. Tesla shares were down nearly 1% pre-market.</li><li>Novo Nordisk AS (NVO): Novo Nordisk has entered into a definitive agreement with Akero Therapeutics Inc. (AKRO) to acquire the latter in a $5.2 billion deal. Novo shares were down nearly 2% in Thursday’s pre-market session.</li><li>Delta Air Lines Inc. (DAL): Delta shares soared over 5% in Thursday’s pre-market trade after the airline’s third-quarter (Q3) results beat Wall Street expectations. Delta reported earnings per share (EPS) of $1.71 on revenue of $16.67 billion, beating analyst estimates of an EPS of $1.53 on revenue of $15.08 billion, according to Stocktwits data.</li><li>PepsiCo Inc. (PEP): PepsiCo shares gained nearly 2% pre-market after the company’s Q3 results beat Wall Street expectations. PepsiCo reported EPS of $2.29 on revenue of $23.94 billion, beating analyst estimates of an EPS of $2.26 on revenue of $23.84 billion, according to Stocktwits data.</li></ul>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-minutes-half-officials-expect-two-more-rate-cuts-by-end-of-2025/ch6EAFlR30c">Fed Minutes Show Officials Agree Rate Cuts Needed, But Inflation Concerns Persist</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk by the New York Stock Exchange

Dow Futures Inch Up As Wall Street Awaits Jerome Powell’s Speech: TSLA, NVO, DAL, PEP Among Stocks To Watch

While Dow Jones futures edged up by 0.01% at the time of writing, the S&P 500 futures were down by 0.02%.

Akero Therapeutics, Inc. (AKRO) announced on Thursday that it has entered into a definitive agreement to be acquired by Danish drugmaker Novo Nordisk (NVO) for up to $5.2 billion in cash.Akero shareholders will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3163964/0/en/Akero-Therapeutics-to-be-Acquired-by-Novo-Nordisk-for-up-to-5-2-Billion.html">receive</a> $54 per share in cash at closing in addition to a contingent value right that entitles holders to a cash payment of $6/ share upon full U.S. regulatory approval of Efruxifermin (EFX) for treatment of compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) by June 30, 2031.&nbsp;The upfront cash payment represents a premium of over 16% from the stock’s last closing price on Wednesday. <a href="https://stocktwits.com/symbol/AKRO">Shares of AKRO</a> soared 19% in Thursday’s pre-market session.On Stocktwits, retail sentiment around AKRO stock rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Novo said that MASH is closely linked with its expertise in diabetes and obesity, with over 40% MASH patients also having type 2 diabetes, and over 80% of MASH patients being overweight or living with obesity.“If approved, we believe it (Efruxifermin) could become a cornerstone therapy, alone or together with Wegovy (semaglutide), to tackle one of the fastest-growing metabolic diseases of our time,” said Novo Nordisk CEO Mike Doustdar.The transaction is expected to close around year-end, the company said, subject to approval by Akero shareholders. It will also be debt-financed, it added.Novo <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916433">said</a> that the transaction is not expected to impact its previously communicated operating profit outlook for 2025. However, the free cash flow outlook for 2025 is expected to be negatively impacted by about $4 billion, it noted.In 2026, Novo expects the acquisition to increase research and development costs and negatively impact full-year operating profit growth by around three percentage points.AKRO shares rose 67% this year and by 63% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/delta-ceo-ed-bastian-says-airline-operations-unaffected-by-federal-government-shutdown-report/ch67Fg9R3Kf">Delta CEO Ed Bastian Says Airline Operations Unaffected By Federal Government Shutdown: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Akero Therapeutics is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

What’s Driving The Super Rally In Akero Shares On Thursday Morning?

Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right. 

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Akero Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

AKRO
Akero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AKRO News

AKROAkero Therapeutics Inc